

【総説】

第12回 高安賞最優秀論文賞受賞

論文 「Glycogen synthase kinase 3 β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O⁶-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling」
Carcinogenesis
第34巻第10号 2206頁~2217頁 2013年10月掲載
Ilya V. Pyko

グリコーゲンシンターゼキナーゼ-3 β の阻害によるc-Mycを介したMGMT promoterメチル化促進に起因する膠芽腫細胞のテモゾロミド感受性増強効果

Pyko V. Ilya (ぴこ いりあ)

背景：セリン・スレオニンキナーゼの1種であるグリコーゲンシンターゼキナーゼ-3 β (GSK3 β)は膠芽腫を含めたヒト癌の悪性形質に関与すると報告されている。現在、膠芽腫に対しては標準治療薬としてテモゾロミドが使用され、その有効性は腫瘍組織内の薬剤抵抗分子O⁶-methylguanine DNA-methyltransferase (MGMT)の有無によって予測可能である。本研究ではGSK3 β 阻害によるテモゾロミドに対する膠芽腫細胞の感受性増強作用とそのメカニズムを解析した。

方法：GSK3 β 阻害医薬品を使用する再発膠芽腫を対象とした臨床試験で得られた初発時、剖検時の摘出検体を用いてMGMTの免疫染色とMGMT promoterのメチル化解析にmethylation-specific polymerase chain reaction (MSP)を行った。4種類の膠芽腫細胞株 (T98G, U138, U251, U87)を用いてGSK3 β の特異的阻害剤およびsmall interfering RNA (siRNA)によるTMZ感受性増強効果を増殖アッセイによって調べた。そのメカニズムをMSP, メチル化の定量のためにMethyLight assay, MGMT発現量の定量のためにQRT-PCR, MGMT promoterに結合する分子を同定するためにCHIP assayを行った。

結果：GSK3 β 阻害医薬品の投与を受けた剖検検体でGSK3 β の基質であるグリコーゲンシンターゼのリン酸化の抑制が認められるとともにMGMTの発現が低下していた。膠芽腫細胞株においてテモゾロミドとGSK3 β 阻害剤の併用は相加的、相乗的な細胞増殖抑制効果を示した。GSK3 β 阻害によりMGMT promoterのメチル化は促進しMGMTの発現は抑えられた。そのメカニズムとしてc-MycがMGMT promoterに結合しDNMT3Aがリクルートされることが明らかとなった。

結論：GSK3 β 阻害によるテモゾロミドに対する膠芽腫細胞の感受性増強作用は、c-Mycを介してMGMT promoterのメチル化が促進されMGMTの発現が抑えられることに起因すると考えられた。これは膠芽腫に対してテモゾロミドと併用するGSK3 β 阻害療法の正当性を支持する基礎基盤となる結果である。

I. Introduction

Glioblastoma (GBM) is the most frequent malignant tumor of the brain and is highly unresponsive to the currently available anticancer treatments. The proliferative and invasive activity of GBM¹⁾ hinders curable surgical intervention, and makes GBM highly resistant to radiation and chemotherapy²⁾. Consequently, there is an urgent need to develop new treatment modalities represented by molecular target-directed therapies.

O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation is an independent favorable prognostic factor in patients with GBM³⁾. The levels of MGMT gene promoter methylation are associated with MGMT expression and are important in setting the transcriptional state of the MGMT promoter through changes in chromatin structure. Methylation status of the promoter is implicated in chemosensitivity to temozolomide (TMZ)³⁾.


Glycogen synthase kinase 3 β (GSK3 β) is a serine/threonine protein kinase involved in human cancers including glioblastoma. We have previously demonstrated that GSK3 β inhibition enhances temozolomide effect in glioma cells. In the report, we have investigated the molecular mechanisms of sensitization of glioblastoma cells to temozolomide by GSK3 β inhibition, focusing on O⁶-methylguanine DNA methyltransferase (MGMT) gene silencing. Glioblastoma tissues from patients treated with the GSK3 β -inhibiting drugs were subjected to immunohistochemistry and methylation-specific PCR assay. Human glioblastoma cell lines T98G, U138, U251 and U87 were treated with a small-molecule GSK3 β inhibitor, AR-A014418 or GSK3 β -specific small interfering RNA. The combined effect of

temozolomide and AR-A014418 on cell proliferation was determined by AlamarBlue assay and an isobologram method. MGMT promoter methylation was estimated by methylation-specific PCR and MethyLight assay. MGMT gene expression was evaluated by real-time quantitative reverse transcriptase-PCR. c-Myc and DNA (cytosine-5)-methyltransferase 3A binding to the MGMT promoter was estimated by chromatin immunoprecipitation assay. GSK3 β inhibition decreased phosphorylation of glycogen synthase and reduced MGMT expression and increased MGMT promoter methylation in clinical tumors. In glioblastoma cell lines, GSK3 β inhibition decreased cell viability, enhanced temozolomide effect and downregulated MGMT expression with relevant changes in the methylation levels of the MGMT promoter. Here, we showed for the first time that c-Myc binds to the MGMT promoter with consequent recruitment of DNA (cytosine-5)-methyltransferase 3A, regulating the levels of MGMT promoter methylation. The results of this study suggest that GSK3 β inhibition enhances temozolomide effect by silencing MGMT expression via c-Myc-mediated promoter methylation.

II. Results and discussion

1) GSK3 β inhibition and glioma cell viability

To determine the function of GSK3 β in the glioma cell lines, we used siRNA to specifically knockdown endogenous GSK3 β . Depletion of GSK3 β , confirmed by Western blot analysis, significantly decreased cell viability in T98G and U251 cells. To



Carcinogenesis
第 34 卷第 10 号 2206 頁 ~ 2217 頁 2013 年 10 月掲載
Fig. 1. The combined effect of TMZ and a GSK3 β inhibitor (AR-A014418) on glioblastoma cells. The relative cell viability of T98G cells after treatment for 144 h with temozolomide (TMZ; 50, 100, 200, and 400 μ mol/L) or AR-A014418 (5, 10, and 20 μ mol/L), alone or in different combinations shown below the panel, measured by the AlamarBlue assay. The relative viability of the cells treated with DMSO alone was scored as 1.0. *, $p < 0.05$; **, $p < 0.01$; AR, AR-A014418; Mann-Whitney U Test, compared to DMSO-treated cells; bars show SD.

further assess the effect of inhibition of GSK3 β activity, we treated the cells with dose-escalating AR-A014418. Cell viability was decreased by AR-A014418 treatment in T98G and U251 cells. Depletion of total and tyrosine 216-phosphorylated GSK3 β by AR-A014418 was observed in glioma cells by Western blot analysis.

2) Combined effect of GSK3 β inhibitor and TMZ in GBM cells

To investigate whether GSK3 β inhibition enhances TMZ effect, T98G, U138 and U87 cells were treated with different doses of TMZ or AR-A014418, alone or in combination. In our study, T98G and U138 cells appeared to be highly resistant to TMZ treatment, and this can be attributed to high MGMT gene expression level in these cell lines. The combination of low-dose AR-A014418 and TMZ significantly reduced cell viability compared to the treatment with TMZ or low-dose AR-A014418 alone (Figure 1).

We showed that GSK3 β inhibition enhanced TMZ effect in T98G cells to sensitivity levels seen in TMZ-sensitive cell lines, whereas U138 demonstrating lower basal MGMT expression showed additive and moderate synergistic effect, while mainly additive effect was noted in U87 and in U251 with undetectable and low MGMT expression, respectively.

3) Effect of GSK3 β inhibition on MGMT promoter methylation status and gene expression

To investigate the influence of GSK3 β inhibition on MGMT promoter methylation, a MSP assay was performed in T98G, U251 and U138 cells expressing MGMT. AR-A014418 treatment decreased or ablated unmethylated MGMT promoter in T98G, increased methylated MGMT promoter in U251 and decreased unmethylated MGMT promoter in U138 cells. MSP assay data were confirmed by the MethyLight assay showing that GSK3 β inhibition increased methylation of CpG islands in the MGMT promoter in T98G, U251 and U138 cells after treatment with AR-A014418. Consistent with the changes in methylation levels, GSK3 β inhibition by AR-A014418 decreased the levels of MGMT gene expression in T98G, U138 and U251 cells as measured by QRT-PCR. Consistently, MGMT protein expression was decreased by AR-A014418 treatment in T98G and U138.

4) Effect of GSK3 β inhibition on c-Myc and DNMT3A binding to the MGMT promoter

To investigate the molecules that are responsible for the changes in MGMT promoter methylation status, we focused on c-Myc signaling. c-Myc is a good candidate


since GSK3 β inhibition increases c-Myc expression in U251⁴⁾, T98G, U138 and U87 cells, as shown by Western blot analysis and QRT-PCR.

Concomitant treatment with the c-Myc inhibitor and AR-A014418 maintained the fraction of unmethylated MGMT promoter in T98G, U251 and U138 cells as shown by MSP assay, suggesting that c-Myc plays a role in MGMT promoter methylation in the GBM cells. MethyLight assay demonstrated that c-Myc inhibitor abrogated the AR-A014418-induced increase of MGMT promoter methylation in all cells. The results of MSP and MethyLight assays collectively suggest that c-Myc-mediated signaling is responsible for MGMT promoter methylation induced by the GSK3 β inhibitor in the GBM cells.


c-Myc is an important factor in cell proliferation that enables G1/S cell cycle progression⁵⁾. A previous report demonstrated that c-Myc has a suppressive effect in human GBM cells, as c-Myc upregulation is associated with increased apoptosis⁴⁾. c-Myc expression is increased in GBM cells by GSK3 β inhibition via its effects on c-Myc phosphorylation and in some cell lines its effect on β -catenin-mediated gene transcription.

c-Myc is known to selectively target DNMT3A to the promoter of the gene, resulting in DNA methylation *de novo* and silencing of the targeted promoter⁶⁾. However, there are no studies showing binding of c-Myc to the MGMT promoter, despite the presence of an E-box transcription factor-binding site in the MGMT promoter. In this study, we hypothesized that a high expression level of c-Myc in GBM cells induced by GSK3 β inhibition induces c-Myc binding to the E-box, resulting in transcriptional repression via recruitment of DNMT3A.

We examined possible interaction between c-Myc and DNMT3A by the ChIP assay. In ChIP assay, c-Myc binding to the E-box transcription factor binding site in the MGMT promoter was on detectable level in U138 and below the limit of quantitation in T98G in DMSO-treated control, whereas AR-A014418 treatment increased c-Myc binding to the same site in the MGMT promoter in both cell lines. This finding was accompanied by increased DNMT3A binding to the same region in the MGMT promoter in T98G and U138 cells (Figure 2A, B). These data suggest that, in response to GSK3 β inhibition, c-Myc recruits DNMT3A to the MGMT promoter, which increases its methylation level in T98G and U138 cells. Our ChIP assay demonstrated for the first time that c-Myc binds to the MGMT promoter in intact cells and that c-Myc and DNMT3A binding to the MGMT promoter increases after AR-A014418 treatment. The mediation of c-Myc for



Carcinogenesis
第 34 卷第 10 号 2206 頁 ~ 2217 頁 2013 年 10 月掲載
Fig. 2. Epigenetic silencing of MGMT expression by GSK3 β inhibition. (A, B) Comparison by ChIP assay of the binding of histone H3, c-Myc, DNMT3A, and FLAG to the E-box site in the MGMT promoter between the GBM cells treated with DMSO or with a GSK3 β inhibitor (AR-A014418). T98G and U138 cells were treated for 72h with DMSO or 5 μ mol/L of AR-A014418. The amount of DNA coprecipitated with the antibody to each molecule was measured by qPCR with a set of primers specific to the E-box transcription factor-binding site in the MGMT promoter. *BLQ, below the limit of quantitation. The figure shows the representative data from two independent immunoprecipitations.



Carcinogenesis
第 34 卷第 10 号 2206 頁 ~ 2217 頁 2013 年 10 月掲載
Fig. 3. Regulation of MGMT expression by GSK3 β signaling. GSK3 β inhibition results in c-Myc activation directly and via activation of β -catenin-mediated signaling, which consequently increases recruitment of DNMT3A by c-Myc to the MGMT promoter, thus increasing *de novo* DNA methylation in the MGMT promoter. The methylated status of the MGMT promoter increases the sensitivity of GBM to TMZ.

recruitment of DNMT3A to the MGMT promoter was confirmed by comparison of data from the conventional ChIP assay, which includes a one-step protein and chromatin fixation with formaldehyde, and data from the ChIP assay with a two-step protein and chromatin fixation. Conventional ChIP assay, which effectively detects direct protein/DNA binding, did not reveal detectable DNMT3A binding to the MGMT promoter. In contrast, ChIP assay with a two-step protein and chromatin fixation provides effective detection of both direct protein/DNA binding, and indirect protein/protein/DNA binding. Consequently, our ChIP assay with a two-step protein and chromatin fixation showed detectable DNMT3A binding to the MGMT promoter with an increased binding level in GBM cells treated with AR-A014418. This was consistent with an increase in c-Myc binding after AR-A014418 treatment, suggesting recruitment of DNMT3A by c-Myc to the MGMT promoter (Figure 2A, B).

Based on our data, we speculate that GSK3 β inhibition eliminates the suppressive effect of GSK3 β on c-Myc expression by the effects on c-Myc phosphorylation, which subsequently increases recruitment of DNMT3A by c-Myc to the MGMT promoter in GBM cells. The interaction between c-Myc and DNMT3A would then activate DNA methyltransferase, which increases local *de novo* DNA methylation in the CpG islands of the MGMT promoter. MGMT promoter methylation silences MGMT gene expression, and this finally sensitizes GBM cells to TMZ (Figure 3).

III. Conclusion

In our clinical research, the GSK3 β -inhibiting drugs inhibited glycogen synthase phosphorylation and decreased MGMT expression, a predictor for resistance to TMZ, in tumor cells in patients with recurrent GBM. Consistent with these findings, the status of the MGMT promoter changed from unmethylated to methylated after treatment with GSK3 β -inhibiting drugs. These data suggest that GSK3 β inhibition decreases MGMT production in GBM affecting the methylation status of the MGMT promoter. This observation in patient tumors was extrapolated by novel findings in this study, demonstrating that GSK3 β inhibition in GBM cells induced c-Myc-dependent recruitment of DNMT3A,

leading to MGMT promoter methylation and consequent silencing of MGMT expression (Figure 2A and B). The provided data will facilitate the development of an optimal combination of GSK3 β inhibitor and alkylating agents for their use in the treatment of patients with GBM.

Acknowledgements

I would like to express my very great appreciation to all the members of Juzen medical association.

It is a great honor for me to receive Takayasu prize for my PhD project.

I would also like to thank the staff of neurosurgery department at Kanazawa University Hospital and division of translational and clinical oncology at Cancer Research Institute with my particular gratitude to late Professor Jun-Ichiro Hamada and special thanks to Professor Toshinari Minamoto and Assistant Professor Mitsutoshi Nakada. Only their continuous support and valuable advices have made it possible to obtain the prize.

I wish to thank my wife and parents for their constant support and encouragement throughout my study.

Finally, I would like to thank all the staff of Kanazawa University for their help and kind assistance during last 5 years.

References

- 1) DeAngelis, L.M. (2001) Brain tumors. *N Engl J Med*, 344, 114-23.
- 2) Lefranc, F., et al. (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. *J Clin Oncol*, 23, 2411-22.
- 3) Hegi, M.E., et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med*, 352, 997-1003.
- 4) Kotliarova, S., et al. (2008) Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. *Cancer Res*, 68, 6643-51.
- 5) Steiner, P., et al. (1995) Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. *EMBO J*, 14, 4814-26.
- 6) Brenner, C., et al. (2005) Myc represses transcription through recruitment of DNA methyltransferase corepressor. *EMBO J*, 24, 336-46.



Profile

所属：金沢大学がん進展制御研究所腫瘍制御研究分野

2003年 Belarusian State Medical University - Minsk, Belarus (summa cum laude) 卒業

2013年 金沢大学大学院医学系研究科修了